The interaction between the receptor FLT3 (FMS-like tyrosine kinase-3) and its ligand FL leads to crucial signalling during the early stages of the commitment of haematopoietic stem cells. Mutation or over-expression of the FLT3 gene, leading to constitutive signalling, enhances the survival and expansion of a variety of leukaemias and is associated with an unfavourable clinical outcome for acute myeloid leukaemia (AML) patients. In this study, we used a murine cellular model for AML and primary leukaemic cells from AML patients to investigate the molecular mechanisms underlying the regulation of FLT3 gene expression and identify its key cis-and trans-regulators. By assessing DNA accessibility and epigenetic markings, we defined regulatory domains in the FLT3 promoter and first intron. These elements permit in vivo binding of several AML-related transcription factors, including the proto-oncogene MYB and the CCAAT/enhancer binding protein C/EBPa, which are recruited to the FLT3 promoter and intronic module, respectively. Substantiating their relevance to the human disease, our analysis of gene expression profiling arrays from AML patients uncovered significant correlations between FLT3 expression level and that of MYB and CEBPA. The latter relationship permits discrimination between patients with CEBPA mono-and bi-allelic mutations, and thus connects two major prognostic factors for AML.
INTRODUCTION
Acute myeloid leukaemia (AML) represents a biologically and clinically heterogeneous disorder characterised by a clonal expansion of haematopoietic progenitor cells blocked in their maturation. About 50% of AMLs present cytogenetic abnormalities of various types that can be used to categorise the patients into different risk groups. The remaining cytogenetically normal AML (CN-AML) can be subdivided based on molecular markers, such as mutations in the genes encoding the FLT3 receptor, C/EBPa, NPM1, IDH1 and IDH2, C-KIT, RAS or WT1. 1 Constituting some of the most frequent mutations found in CN-AML, mutations in the FLT3 gene generally associate with an inferior outcome. The FMS-like tyrosine kinase-3 (FLT3), a member of the Type III RTK subfamily, is a membrane-bound tyrosine kinase receptor, which together with its ligand FL, has an important role in the normal development of stem cells and the immune system. 2, 3 The FLT3 protein is commonly mutated in AML, with 20-30% of cases carrying an internal tandem duplication within the juxtamembrane domain (FLT3-ITD) and 8-12% a single point mutation at position 835 in the kinase domain (FLT3-D835), leading to constitutive signalling and enhanced cell survival and proliferation. While the presence of the FLT3-ITD mutation significantly correlates with adverse clinical outcome, the prognostic significance of FLT3 single point mutations remains unclear (see 4 for review). By themselves, FLT3-ITD mutant proteins are sufficient to induce a myeloproliferative disorder, but the development of FLT3-ITD AML may require additional mutations that impair haematopoietic differentiation. 5 In this respect, the functional cooperation between FLT3-ITD and mutation of the CCATT/enhancer binding protein alpha (C/EBPa) may be of particular significance in CN-AML. 6, 7 C/EBPa is a leucine-zipper transcription factor that has a pivotal role in granulocyte and neutrophil development 8 but also act as a tumour suppressor in the haematopoietic system. 9 As the result of an alternative translation initiation, C/EBPa is produced in two major isoforms, p42 (42kDa) and p30 (30kDa). Mutations of the CEBPA gene are reported in 5-14% of patients with AML and can be largely categorised into two types: the N-terminal stop mutations that result in the expression of the p30 isoform from the mutated allele and the C-terminal inframe insertions/deletions within the basic region leucine zipper DNA binding domain. 10, 11 In most cases, CEBPA mutations are bi-allelic with one allele harbouring the N-terminal mutation and the other the Cterminal, while the homozygous N-or C-terminal mutations are relatively rare. 12 Several studies have demonstrated that bi-allelic mutations of the CEBPA gene give a favourable prognosis for AML patients, 13 although this benefit appears to be nullified in the presence of FLT3 activating mutations.
14 When coexisting, FLT3-ITD mutations may cooperate in leukaemogenesis by over-riding the differentiation impairment brought about by C/EBPa bi-allelic mutations and promote the formation of committed myeloid progenitors, the templates for leukaemia-initiating cells. 6 In the absence of FLT3 mutation, the auto-activation of the receptor was also reported in patients with high expression level of FLT3, making this feature another poor prognosis marker. 15 As might be expected, the combination of both FLT3-ITD mutation and high-level expression associates with a dismal outcome for patients. Paralleling FLT3 activating mutations, constitutive signalling through FLT3 overexpression may cooperate with other mutations in leukaemogenesis. For instance, such collaboration was suggested with RUNX1 mutation in AML with chromosome 13 trisomy. 16 In light of its clinical relevance, it is surprising that, aside from recent evidence indicating a role for HOXA9 and MEIS1, 17, 18 the mechanisms regulating FLT3 expression in AML remains largely undefined.
In order to investigate the regulators of FLT3 transcription in AML, we made use of a murine-cultured model for CN-AML and bone marrow samples from CN-AML patients. We identified two enhancers regulating FLT3 expression by allowing recruitment of several AML-related transcription factors. Among these, we identified the transcription factor MYB, which is increasingly implicated as a key component of leukaemia maintenance and oncogene addiction, and C/EBPa as keys regulators of FLT3 expression in AML. Furthermore, we showed a direct relationship between CEBPA mutation status and FLT3 expression level and highlighted an important molecular connection between these factors in CN-AML cells.
MATERIALS AND METHODS

Cell line
FMH9 cells were cultured in RPMI medium supplemented with 10% foetal bovine serum, 50 ng/ml stem cell factor, 5 ng/ml granulocyte-macrophage colony-stimulating factor, 5 ng/ml interleukin-3 and 5 ng/ml interleukin-6. All the cytokines were purchased from Peprotech EC (London, UK).
AML patient samples
Collected at diagnosis, bone marrow samples of de novo AML patients were obtained through the Central England Haemato-oncology Research Biobank and used for Ficoll-Plaque separation of white mononucleated cells.
X-ChIP
X-ChIP assays were performed as previously described, 19 Millipore, Billerica, MA, USA) (MYB) or locally produced antibodies (H3K9ac, H4K8ac).
Nuclease hypersensitive site mapping
Cell nuclei, prepared in 1 ml digestion buffer (15 mM Tris-HCl pH7.5, 15 mM NaCl, 60 mM KCl, 5 mM MgCl 2 , 300 mM glucose, 0.5 mM EGTA, 0.1%NP40), were digested 10 min at 37 1C with DNase I (0-60units). The reaction was terminated by adding 330 ml of 100 mM EDTA/4% SDS. RNA and proteins were sequentially digested at 37 1C with 100 mg RNaseA (1 h) and 100 mg proteinase K (overnight). Extracted DNA was used as template for quantitative-PCR reactions (primers listed in Supplementary Table S1 ).
Patient profiling arrays
AML patient CEL files were analysed using MAS (background), INVARIANT SET (normalisation), MAS (pm correct) and LIWONG (summary) methods as recommend for gene coexpression analysis. 20 Intensities were mean centred to account for undesirable variations (Supplementary Figure S2) . The respective scaling factors are listed in Supplementary Table S2 . For transcripts represented by multiple probes on the array, the average value of the different probes was determined. The log10 values of the gene expression from all 46 CN-AML CEBPA wild-type profiling arrays in the data set GSE15210 were used for the calculation of the Pearson correlation coefficient. Within the larger GEO data set GSE14468 containing a mix of CN and abnormal AML cases, 58 profiling arrays from CN-AML of M0 to M3 subtypes (according the French-American-British classification system) with no CEBPA mutations were identified and used for this study as well as seven CN-AML with a CEBPA monoallelic N-terminal stop mutation and 25 CN-AML arrays of patients with CEBPA bi-allelic mutations.
Plasmids and transfection method
In total, 5 Â 10 6 FMH9 cells were electroporated using the Amaxa transfection kit (Biosystems, Warrington, UK) according to the manufacturer's instructions. The expression vectors for the wild-type form of C/EBPa and MYB as well as the correspondent small hairpin RNA (shRNA) were purchased from Origene (Cambridge, UK). The C/EBPa mutant constructs (Supplementary Figure S3) , kindly provided by Toshio Kitamura, were as described. 7 
RESULTS
The FMH9 cell line recapitulates AML cell features To define the mechanism underlying FLT3 gene regulation in leukaemia, we used a murine cell line modelling CN-AML. The FMH9 line was obtained from primary bone marrow progenitors cotransduced with HOXA9 and MEIS1, a combination causal for AML. 18, 21, 22 Parallel morphological and flow cytometric analyses with patient cells confirmed the FMH9 AML-like phenotype (Figure 1a) . Expressing the surface markers GR-1, CD11b, KIT and FLT3, the transformed murine myeloblastic FMH9 cells mimic a CD14 þ /CD11b þ /CD38 þ /c-Kit þ /Flt3 þ leukaemic fraction of CN-AML patient bone marrow (Figure 1b) . Crucially, mRNA quantification indicated similar levels of FLT3 expression in FMH9 and AML patient cells (Figure 1c ).
Flt3 cis-regulatory modules lie in the promoter and first intron The Flt3 gene is characterised by an abundance of repeated sequences and an overall low degree of cross-species sequence conservation. On the basis that crucial cis-regulatory domains are preserved across species, we focussed on scrutinising the regions Figure 3 . Detection of transcription factor binding at the sites of nuclease hypersensitivity. Relative enrichments were determined against the immunoglobulin G control material by quantitative-PCR at the location of the hypersensitive regions (HSA to C at À 1.45, À 0.15 and þ 7.5 kb relative to the Flt3 initiating codon) and normalised against two internal control regions (at À 3.5 and À 0.27 kb from the ATG). Error bars represent the s.e. of the mean. All plots are representative of a minimum of three independent experiments used to determine the two-tailed P-value by paired t-test: ***o0.001 and **o0.01. Relative enrichments were determined against the immunoglobulin G control material and normalised against the control region (at À 6.95 kb from the ATG). Error bars represent the s.e. of the mean. C/EBPa ChIP plots are representative of three independent experiments used to determine the two-tailed P-value by paired t-test. MYB ChIP plots represent patient-specific experiments for which the P-values were calculated using replicate measurements. P-value indications ***o0.001, **o0.01 and *o0.05.
regions ( Figure 3 ). In agreement with the previous works, 17, 18 we identified direct binding of HOXA9 and MEIS1 to the Flt3 promoter in the AML-like FMH9 line, which ectopically expresses both factors. Interestingly, these data also show direct recruitment of MYB and C/EBPa to the Flt3 promoter and enhancer module, respectively.
FLT3 expression correlates with that of HOXA9, MEIS1, MYB and CEBPA in CN-AML The abundance of the aforementioned factors and their potential influence on FLT3 expression were next evaluated in CN-AML. For this purpose, we made use of publicly available data sets of AML patient profiling arrays and assessed the relationship between the expression of FLT3 and its predicted regulators. Evaluating gene expression codependency, the Pearson correlation coefficients were calculated between the logarithmic expression of FLT3 and the different candidate factors. As C/EBPa is included in this list, the analysis was restricted to patients with no CEBPA mutations, summing 46 and 58 CN-AML arrays within two independent sets (Geo data sets GSE15210 and GSE14468, respectively). Remarkably, despite the biological heterogeneity and variety of genomic mutations included within and between the sets, the analysis showed that FLT3 RNA expression is linked to that of CEBPA, MYB, MEIS1 and HOXA9 in CN-AML (Figure 4) . Together with our finding that all four proteins are recruited to the Flt3 promoter and intronic regions in the FMH9 line, these data strongly suggest that MYB and C/EBPa have a determining role alongside HOXA9 and MEIS1 in the control of FLT3 expression in CN-AML.
MYB and C/EBPa bind to the human FLT3 promoter and intronic elements in CN-AML cells To confirm that our findings using the FMH9 line were representative of the human disease condition, we reproduced the nuclease assays and X-ChIP experiments using cells from different CN-AML patients. As shown in Figure 5a , the human FLT3 locus has a large number of insertions compared with the murine locus. However, the three identified regions are found conserved at À 15.3 kb, À 0.37 kb and þ 6.2 kb from the human FLT3 initiating codon. The intronic region C was split into two regions (hC1 and hC2) by the presence of a repeated sequence. At these locations, DNaseI hypersensitive sites were only consistently found in regions A and C in CN-AML patient cells (Figure 5b ). In agreement with our findings using the murine line, X-ChIP experiments demonstrated the binding of MYB and C/EBPa in human AML to regions A and C on the FLT3 locus, respectively (Figure 5c ). MYB and C/EBPa expression levels influence Flt3 expression To investigate the extent to which MYB and C/EBPa contribute to the regulation of Flt3 transcription, we manipulated their levels through shRNA knockdown and over-expression in the murine FMH9 AML model. Both shRNA-mediated silencing and overexpression of MYB and C/EBPa were achieved by transient transfection, 24 h after which Flt3 RNA levels were measured by quantitative-PCR. Reduction or over-expression of MYB led to a parallel down-and upregulation of Flt3 expression in the AML-like cells (Figure 6 upper panels) . In contrast, while C/EBPa silencing also led in a decrease in Flt3 RNA levels, enforced C/EBPa expression only resulted in a moderate elevation of its transcript accompanied by a marked downregulation of Flt3 expression (Figure 6 lower panel) . This latter result suggests that regulation of Flt3 expression could depend on strict C/EBPa activity thresholds in AML.
FLT3 expression is affected in CN-AML with CEBPA bi-allelic mutation The latter finding raised the question of the impact that CEBPA mutations may have on FLT3 expression regulation in CN-AML. To Regulation of FLT3 expression in AML G Volpe et al address this question, we assessed and compared the relationship between FLT3 and CEBPA expression in patients with different CEBPA status. Pearson correlations were determined using expression profiling arrays of CN-AML with wild-type CEBPA, CEBPA monoallelic N-terminal stop mutation (expressing the C/EBPa p30 isoform) and CEBPA bi-allelic mutations. The results revealed that the log linear relation between FLT3 and CEBPA transcript expression were conserved in patients with a CEBPA mono-allelic N-terminal stop mutation but lost in the presence of CEBPA bi-allelic mutations (Figures 7a and b) . As the loss of this relationship would be consistent with an impairment of C/EBPamediated FLT3 transcriptional regulation, we proceeded to evaluate how FLT3 expression may be affected in this subgroup of patients by plotting and comparing FLT3 transcript levels in patients with different CEBPA status (Figure 7c ). This analysis showed that CEBPA bi-allelic mutations associate with a decrease in the median expression level of FLT3.
The signature of FLT3 constitutive activation is largely inverted in CN-AML with CEBPA bi-allelic mutation To test whether this reduced FLT3 expression could affect the receptor function and assess how this may compare with the effects of the FLT3-ITD activating mutation, we analysed the expression of genes that were shown to be downstream targets of FLT3-ITD signalling (Figure 8a ) and components of the FLT3-ITD molecular signature in CN-AML (Figure 8b ). These encompass (i) genes that were shown to be upregulated (PIM-1) or repressed (CEBPA, RGS2 and PU.1) by the FLT3-ITD signalling pathway 23, 24 ( Figure 8a) ; and (ii) genes that participate in the signature of the FLT3-ITD mutation, predicting an adverse clinical outcome in patients presenting a combination of elevated (genes listed Figure 8b , left panel), and reduced (PDE4A, GNG2) transcript levels. 25 The comparison of the RNA abundance between CN-AML patients with wild type or bi-allelic mutations of CEBPA revealed that most genes were differently expressed in the two groups. Associating with CEBPA mutations, variations in PIM-2 and CEBPA expression were inversed to their response to FLT3-ITD signalling (Figure 8a) . Strikingly, the FLT3-ITD molecular signature, as determined against the wild-type receptor cases, 25 was largely inverted in CN-AML patients with CEBPA bi-allelic mutations when compared with their wild-type counterparts (Figure 8b ).
DISCUSSION
Using a murine myeloid leukaemia model and bone marrow cells from AML patients, our study highlights the role of the transcription factors MYB and C/EBPa in the regulation of FLT3 expression in the leukaemia context.
The cooperative activities of MYB and C/EBPa in activating the promoter of myeloid genes have been previously reported. 26, 27 However, FLT3 constitutes a target of particular significance for both proteins in the context of AML. Having a determinant role in the maintenance and function of the haematopoietic stem cell compartment, 28 MYB activity also associates with a broad spectrum of haematological malignancies, including CML, T-ALL and AML. [29] [30] [31] Notably, MYB was reported to have a critical role for the transforming potential of the AML-inducing fusion protein MLL-ENL. 31 However, its function and target genes in the leukaemia context remain poorly understood. Here, by identifying the FLT3 receptor gene as a direct target of MYB in AML cells, our study places MYB activity upstream to that of FLT3 and thus gives a first indication as to how the proto-oncogene MYB may influence the proliferation and survival of AML cells.
Our work suggests that, together with HOXA9 and MEIS1, MYB and C/EBPa are important elements of the combinatorial binding of leukaemia-related transcription factors that regulate FLT3 expression. The role of HOXA9 and MEIS1 in FLT3 regulation, and their recruitment to its promoter, had been previously reported. 18 In addition, the recent study of Huang et al.
17
considered the existence of enhanceosomes containing these proteins and hinted at the wider relevance of these types of complexes in the regulation of myeloid and leukaemia-related target genes. By analysing the over representation of conserved transcription factor binding sites in the vicinity of HoxA9 and Meis1 binding locations, the authors identified both C/EBPa and MYB as candidate components of these enhanceosomes and suggested a contribution of PU.1. This member of the ETS family of transcription factors was shown to regulate FLT3 expression in dendritic cells 32 and to cooperate with C/EBPa and MYB in regulating the transcription of the neutrophil elastase gene. 26 Thus, one may expect that a similar collaborative mechanism may underlie the regulation of FLT3 expression. However, we found no evidence of PU.1 binding to the Flt3 locus in the CN-AML murine model or any indication of a relation between PU.1 and FLT3 expression using the human AML micro-array data. Therefore, in contrast with HOXA9, MEIS1, MYB and C/EBPa, PU.1 does not appear to be a crucial regulator of FLT3 expression in the context of CN-AML cells.
The fact that C/EBPa participates in FLT3 regulation is probably the most clinically relevant finding of the present study, as it constitutes a direct link between two major molecular prognostic markers for AML. The individual importance of both FLT3 and CEBPA status for AML prognosis are well documented. 33, 34 So far, a few hints of a connection between these molecular markers have been given by recent studies showing that the favourable outcome associated with C/EBPa bi-allelic mutations was cancelled out by the presence of FLT3-ITD mutations, 6, 14 that FLT3-ITD signalling inhibits C/EBPa-differentiating function by promoting its phosphorylation, 35 and that C/EBPa with a C-terminal mutation collaborates with FLT3-ITD in inducing AML. 7 Such collaborations may rely on the ability of FLT3 signalling to support myeloid commitment of the expanding CEBPA mutated cells. 6 Our analysis of profiling arrays from AML patients with differing CEBPA status links FLT3 expression and C/EBPa activity. We find that CEBPA bi-allelic mutations associate with lower levels of FLT3 transcript in AML patients. In a bid to assess the influence of C/EBPa mutated forms on Flt3 expression, we introduced N-and C-terminal mutants, singly or in combination, in the FMH9 cell-line (Supplementary Figure S3) . This approach failed to induce statistically significant changes in Flt3 expression, possibly due to the presence of the wild-type form. Similarly, analysis of the profiling arrays did not reveal significant differences in FLT3 expression between patients with-wild type or mono-allelic CEBPA mutations. Conversely, global impairment of C/EBPa activity through shRNA silencing resulted in Flt3 downregulation. Our cell-line based results also suggested that a tight control on C/EBPa expression at the cellular level might prevent any sizeable over-expression. Arguing for the need to maintain such stability, small increases in Cebpa also resulted in reduced Flt3 RNA levels. The explanation for this could lie within a delicate equilibrium between some constituents of the leukaemic transcriptional network. Alternatively, the apparent decrease in Flt3 expression may reflect a change in the cellular context. In fact, small changes in C/EBPa expression may induce granulocytic differentiation of transformed cells, as previously demonstrated in U937 cells. 36 In the context of the disease, it is possible that the lower levels of FLT3 in cells from patients with CEBPA bi-allellic mutations may prevent auto-phosphorylation of the FLT3 receptor that occurs when the FLT3 RNA level exceeds 200 000 copies/mg RNA. 15 This hypothesis would be consistent with the findings that CEBPA biallelic mutations, 13, 37 or more generally loss of DNA-binding activity, 38 associate with a positive prognosis. As this benefit is lost in the presence of FLT3 activating mutations, it would be very interesting to test this theory by assessing whether auto-activation of the FLT3 receptor is less frequent in AML with CEBPA bi-allelic mutations and how this may contribute to the favourable prognosis associated with this status. Here, we analysed the expression level of genes that constitute the molecular signature of CN-AML with FLT3-ITD mutation. 25 With reference to CN-AML with wild-type CEBPA, we found that patients with CEBPA bi-allelic mutations present an inverse expression pattern to that of FLT3-ITD patients. Being regulated in an opposite manner by the wild-type and mutated receptors signalling cascades, 23, 24 CEBPA itself is a notable downstream target. Its elevated expression in patients with bi-allelic mutations further undermines the idea of a FLT3-ITD-related signalling cascade in these patients. Taken together, our results support the hypothesis that the presence of bi-allelic CEBPA mutations may reduce FLT3-mediated leukemogenic signals.
